clinical trial · NCT07658417
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
Novo Nordisk A/S·—·enrolling by invitation·n = 216
Diabetes Mellitus, Type 2Insulin icodec
brief summary
The purpose of this study is to investigate the use of insulin icodec in the real-world setting in a population that broadly reflects people living with T2D and for whom switching to a once-weekly insulin icodec has been deemed relevant and beneficial by the treating physician. The study will last for approximately 30 weeks.
started
Jul 2, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Sep 15, 2026
official title
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol